Zacks: Analysts Anticipate Merus (NASDAQ:MRUS) to Post -$0.66 EPS

Equities research analysts forecast that Merus (NASDAQ:MRUSGet Rating) will post earnings of ($0.66) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Merus’ earnings, with estimates ranging from ($0.73) to ($0.56). Merus reported earnings per share of ($0.28) in the same quarter last year, which indicates a negative year-over-year growth rate of 135.7%. The company is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Merus will report full year earnings of ($2.94) per share for the current year, with EPS estimates ranging from ($3.62) to ($2.19). For the next financial year, analysts expect that the firm will report earnings of ($3.10) per share, with EPS estimates ranging from ($4.13) to ($1.47). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Merus.

Merus (NASDAQ:MRUSGet Rating) last posted its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.24. The firm had revenue of $14.71 million for the quarter, compared to the consensus estimate of $12.39 million. Merus had a negative net margin of 135.65% and a negative return on equity of 27.26%.

Several research firms recently issued reports on MRUS. StockNews.com initiated coverage on Merus in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research lowered shares of Merus from a “buy” rating to a “hold” rating in a report on Friday, March 4th. Needham & Company LLC assumed coverage on shares of Merus in a report on Thursday, February 10th. They set a “buy” rating and a $45.00 price target for the company. Finally, BMO Capital Markets assumed coverage on shares of Merus in a report on Friday, February 11th. They set an “outperform” rating and a $45.00 price target for the company. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $38.89.

In other news, EVP Peter B. Silverman sold 60,000 shares of the company’s stock in a transaction dated Thursday, March 10th. The shares were sold at an average price of $26.95, for a total value of $1,617,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.90% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale purchased a new stake in shares of Merus in the 4th quarter worth about $127,000. BlackRock Inc. boosted its holdings in shares of Merus by 11.0% during the 3rd quarter. BlackRock Inc. now owns 279,316 shares of the biotechnology company’s stock valued at $6,144,000 after acquiring an additional 27,740 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Merus by 134.9% in the 3rd quarter. Wellington Management Group LLP now owns 5,009,204 shares of the biotechnology company’s stock worth $110,201,000 after purchasing an additional 2,876,971 shares during the period. Macquarie Group Ltd. lifted its stake in shares of Merus by 104.5% in the 3rd quarter. Macquarie Group Ltd. now owns 2,585 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,321 shares during the period. Finally, Citigroup Inc. lifted its stake in shares of Merus by 1,407.9% in the 3rd quarter. Citigroup Inc. now owns 117,297 shares of the biotechnology company’s stock worth $2,581,000 after purchasing an additional 109,518 shares during the period. 53.91% of the stock is currently owned by hedge funds and other institutional investors.

MRUS opened at $21.42 on Friday. Merus has a 12 month low of $16.14 and a 12 month high of $33.09. The business’s 50-day moving average price is $26.13 and its 200-day moving average price is $27.37. The company has a market cap of $932.82 million, a P/E ratio of -12.45 and a beta of 1.00.

Merus Company Profile (Get Rating)

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

See Also

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.